ghk cu peptides GHK-CU – Research Peptide Private label GHK GHK-Cu 100mg

Neither peptide has been through human clinical trials as a therapeutic agent all the safety data is preclinical

CS acknowledges financial support from the Ministry of Education and Science of the Russian Federation, grant 14.Y26.31.0019

Food and Drug Administration U.S

Pharmacokinetics (Coskun et al., Cell Metabolism 2022) Phase 1 PK data established the ~6-day half-life and once-weekly dosing rationale

The nine tissue systems now documented in the preclinical literature were not predicted by computational models or receptor-binding assays at the outset they were identified sequentially as researchers in different laboratories independently tested the compound against different experimental injury models and consistently found meaningful effects

10.1038/s41467-022-32085-7